Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 2/20 | 0.41 |
| ▸ | LDHB | P07195 | 2/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12760104 | 0.88 | CYP3A4 (0.41) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL25329987 | 0.87 | CYP3A4 (0.64) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL29803911 | 0.85 | CYP3A4 (0.42) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL1727042 | 0.85 | CYP3A4 (0.42) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL1104465 | 0.85 | ALDH1A1 (0.48) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3835523 | 0.85 | CYP3A4 (0.42) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL22060772 | 0.85 | CYP3A4 (0.42) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL9871803 | 0.83 | KDM4E (0.44) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL25305035 | 0.83 | ALDH1A1 (0.36) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL31299886 | 0.82 | KDM4E (0.42) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112250700-B | BODIPY (boron dipyrromethene) protein misfolding probe Halo-BODIPY as well as preparation method and application thereof | 南京师范大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114315895-A | Ligand, preparation method and application thereof, and method for preparing linear dialdehyde | 万华化学集团股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-112250700-A | BODIPY (boron dipyrromethene) protein misfolding probe Halo-BODIPY as well as preparation method and application thereof | 南京师范大学 | 2021-01-22 | — | — | CN | claimed |
| EP-2521722-B1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2015-05-06 | — | — | EP | claimed |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2521722-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | AstraZeneca AB (SE) | 2012-11-14 | — | — | EP | claimed |
| WO-2011084098-A1 | PROCESS FOR MAKING A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR - 874 | ASTRAZENECA AB (SE) | 2011-07-14 | — | — | WO | claimed |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| EP-4605387-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| EP-1175401-B1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2004-04-08 | — | — | US | disclosed |
| US-6689765-B2 | VIRICIDES; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-04-10 | — | — | US | disclosed |
| US-6391865-B1 | AIDS THERAPY; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; SKIN DISORDERS | SCHERING CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1175401-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066558-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | CYP3A4 4564/4885ACHE 4337/4885ALDH1A1 3447/4885 |
| US-20130203995-A1 | Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874 | GRM4, GRIK4, GRIA4 | CYP3A4 2238/4885ACHE 2982/4885ALDH1A1 3129/4885 |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CYP3A4 914/4885ACHE 4277/4885ALDH1A1 1737/4885 |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CYP3A4 914/4885ACHE 4277/4885ALDH1A1 1737/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | CYP3A4 4346/4885ACHE 4749/4885ALDH1A1 3818/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | CYP3A4 3058/4885ACHE 3141/4885ALDH1A1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.